Vitamin D supplementation for the treatment of non alcoholic fatty liver disease: a randomized double blind placebo controlled trial
Phase 1
- Conditions
- ON ALCOHOLIC FATTY LIVER DISEASE.
- Registration Number
- IRCT201612077732N2
- Lead Sponsor
- Vice Chancellor for Research, Shiraz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 106
Inclusion Criteria
men and women aged between 20 and 75 years
with presence of hepatic steatosis diagnosed by ultrasound (US)
Exclusion criteria: Patients with liver cirrhosis; patients with hepatitis B or hepatitis C; patients with alcohol consumption (> 10 gr/ day); patients with autoimmune hepatitis; Wilson’s disease and hemochromatosis; known cancer; nephrolithiasis; nephrocalcinosis; chronic renal failure; hypercalcemia; hypercalciurea; pregnancy; lactation; patients receiving estrogen; tamoxifen; methotrexate; amiodarone; tetracycline and those receiving vitamin D and calcium supplementations in previous 6 months.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method iver enzymes. Timepoint: begining of the study-3 months after. Method of measurement: biochemicl kit.
- Secondary Outcome Measures
Name Time Method ipid profile and plasma glucose. Timepoint: begining of the study- 3 months later. Method of measurement: Biochemical kit.